Quick Answer
Xenon Pharmaceuticals Inc. reported Total Revenue of $311.0 thousand for fiscal year 2017.
Xenon Pharmaceuticals Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Revenue (ASC 606) | — | — | — | — | — | — |
| Net Income | -$345.91M -47.6% |
-$234.33M -28.5% |
-$182.39M -45.5% |
-$125.37M -58.9% |
-$78.88M -173.5% |
-$28.84M +30.7% |
| Diluted EPS | -$4.36 -44.9% |
-$3.01 -10.3% |
-$2.73 -32.5% |
-$2.06 -16.4% |
-$1.77 -118.5% |
-$0.81 |
| Total Assets | $633.16M -20.7% |
$798.14M -17.3% |
$964.80M +27.9% |
$754.15M +31.8% |
$572.01M +202.4% |
$189.19M +28.1% |
| Cash and Equivalents | $199.16M +39.6% |
$142.71M -4.0% |
$148.64M +159.7% |
$57.24M -67.4% |
$175.69M +290.3% |
$45.01M +81.8% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $581.76M -22.9% |
$754.90M -18.6% |
$927.92M +28.6% |
$721.50M +31.2% |
$550.03M +221.0% |
$171.35M +86.3% |
| R&D Expense | $300.94M +43.0% |
$210.39M +25.6% |
$167.51M +58.4% |
$105.77M +40.2% |
$75.46M +49.4% |
$50.52M +30.1% |
| Operating Income | -$373.07M -33.6% |
-$279.30M -30.5% |
-$214.05M -65.7% |
-$129.14M -63.5% |
-$78.99M -152.4% |
-$31.30M +26.9% |
| Shares Outstanding | 80.01M +4.7% |
76.42M +1.4% |
75.37M +20.4% |
62.59M +21.2% |
51.63M +47.5% |
35.01M +24.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $264.0K | -36.1% | +1660.0% |
| Revenue (ASC 606) | September 30, 2017 | $264.0K | — | — |
| Net Income | September 30, 2025 | -$90.90M | -44.8% | -7.3% |
| Diluted EPS | September 30, 2025 | -$1.15 | -42.0% | -7.5% |
| Total Assets | September 30, 2025 | $607.84M | -27.3% | -9.9% |
| Cash and Equivalents | September 30, 2025 | $104.51M | +19.3% | -22.8% |
| Long-Term Debt | December 31, 2019 | $10.89M | -27.5% | -7.6% |
| Stockholders Equity | September 30, 2025 | $559.51M | -29.9% | -11.7% |
| R&D Expense | September 30, 2025 | $77.05M | +35.3% | +2.8% |
| Operating Income | September 30, 2025 | -$96.34M | -30.8% | -2.2% |
| Shares Outstanding | September 30, 2025 | 77.12M | +1.7% | +0.2% |
- Xenon Pharmaceuticals Inc. reported Total Revenue of $311.0 thousand for fiscal year 2017.
- Xenon Pharmaceuticals Inc. showed a decrease of -82.8% in Total Revenue compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported Revenue (ASC 606) of $311.0 thousand for fiscal year 2017.
- Xenon Pharmaceuticals Inc. reported Net Income of -$345.91 million for fiscal year 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -47.6% in Net Income compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported Diluted EPS of $4.36 per share (loss) for fiscal year 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -44.9% in Diluted EPS compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported Total Assets of $633.16 million for fiscal year 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -20.7% in Total Assets compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported Cash and Equivalents of $199.16 million for fiscal year 2025.
- Xenon Pharmaceuticals Inc. showed an increase of +39.6% in Cash and Equivalents compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported Long-Term Debt of $10.89 million for fiscal year 2019.
- Xenon Pharmaceuticals Inc. showed a decrease of -27.5% in Long-Term Debt compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported Stockholders Equity of $581.76 million for fiscal year 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -22.9% in Stockholders Equity compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported R&D Expense of $300.94 million for fiscal year 2025.
- Xenon Pharmaceuticals Inc. showed an increase of +43.0% in R&D Expense compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported Operating Income of -$373.07 million for fiscal year 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -33.6% in Operating Income compared to the prior fiscal year.
- Xenon Pharmaceuticals Inc. reported Shares Outstanding of 80.01 million shares for fiscal year 2025.
- Xenon Pharmaceuticals Inc. showed an increase of +4.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: